{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:58:09Z","timestamp":1787957889931,"version":"build-2784847793"},"reference-count":117,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T00:00:00Z","timestamp":1628812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Human Cytomegalovirus (HCMV) infection is widespread and can result in severe sequelae in susceptible populations. Primary HCMV infection of na\u00efve individuals results in life-long latency characterized by frequent and sporadic reactivations. HCMV infection elicits a robust antibody response, including neutralizing antibodies that can block the infection of susceptible cells in vitro and in vivo. Thus, antibody products and vaccines hold great promise for the prevention and treatment of HCMV, but to date, most attempts to demonstrate their safety and efficacy in clinical trials have been unsuccessful. In this review we summarize publicly available data on these products and highlight new developments and approaches that could assist in successful translation of HCMV immunotherapies.<\/jats:p>","DOI":"10.3390\/ijms22168728","type":"journal-article","created":{"date-parts":[[2021,8,15]],"date-time":"2021-08-15T21:43:55Z","timestamp":1629063835000},"page":"8728","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection"],"prefix":"10.3390","volume":"22","author":[{"given":"Evi B.","family":"Struble","sequence":"first","affiliation":[{"name":"Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Murata","sequence":"additional","affiliation":[{"name":"Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Division of Antivirals, Office for New Drugs, Center for Drugs Evaluation and Research, United States Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Scott","sequence":"additional","affiliation":[{"name":"Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,13]]},"reference":[{"key":"ref_1","unstructured":"Kimberlin, D.W., Long, S.S., Brady, M.T., and Jackson, M.A. (2018). Cytomegalovirus Infection. Red Book: 2018 Report of the Committee on Infectious Diseases, American Academy of Pediatrics."},{"key":"ref_2","unstructured":"(2021, August 12). About Cytomegalovirus (CMV), Available online: https:\/\/www.cdc.gov\/cmv\/overview.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"ref_4","first-page":"417","article-title":"Manifestations of human cytomegalovirus infection: Proposed mechanisms of acute and chronic disease","volume":"325","author":"Britt","year":"2008","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1128\/CMR.00043-19","article-title":"Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation","volume":"34","author":"Limaye","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Njue, A., Coyne, C., Margulis, A.V., Wang, D., Marks, M.A., Russell, K., Das, R., and Sinha, A. (2020). The Role of Congenital Cytomegalovirus Infection in Adverse Birth Outcomes: A Review of the Potential Mechanisms. Viruses, 13.","DOI":"10.3390\/v13010020"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1128\/JVI.01500-15","article-title":"Viral Regulation of Cell Tropism in Human Cytomegalovirus","volume":"90","author":"Li","year":"2016","journal-title":"J. Virol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-virology-110615-042422","article-title":"Human Cytomegalovirus Latency: Approaching the Gordian Knot","volume":"3","author":"Goodrum","year":"2016","journal-title":"Annu. Rev. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Diggins, N.L., Skalsky, R.L., and Hancock, M.H. (2021). Regulation of Latency and Reactivation by Human Cytomegalovirus miRNAs. Pathogens, 10.","DOI":"10.3390\/pathogens10020200"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1128\/jvi.66.3.1761-1764.1992","article-title":"A human cytomegalovirus glycoprotein complex designated gC-II is a major heparin-binding component of the envelope","volume":"66","author":"Kari","year":"1992","journal-title":"J. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature07209","article-title":"Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection","volume":"455","author":"Soroceanu","year":"2008","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/nature01818","article-title":"Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus","volume":"424","author":"Wang","year":"2003","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15470","DOI":"10.1073\/pnas.0406821101","article-title":"Cellular integrins function as entry receptors for human cytomegalovirus via a highly conserved disintegrin-like domain","volume":"101","author":"Feire","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10026","DOI":"10.1128\/JVI.00710-10","article-title":"The glycoprotein B disintegrin-like domain binds beta 1 integrin to mediate cytomegalovirus entry","volume":"84","author":"Feire","year":"2010","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cooper, R.S., and Heldwein, E.E. (2015). Herpesvirus gB: A Finely Tuned Fusion Machine. Viruses, 7.","DOI":"10.3390\/v7122957"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1128\/JVI.78.18.10023-10033.2004","article-title":"Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes","volume":"78","author":"Hahn","year":"2004","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1073\/pnas.0509201102","article-title":"Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism","volume":"102","author":"Wang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"11539","DOI":"10.1128\/JVI.01016-06","article-title":"Human cytomegalovirus (HCMV) infection of endothelial cells promotes naive monocyte extravasation and transfer of productive virus to enhance hematogenous dissemination of HCMV","volume":"80","author":"Bentz","year":"2006","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/infdis\/171.2.263","article-title":"Bidirectional transmission of infectious cytomegalovirus between monocytes and vascular endothelial cells: An in vitro model","volume":"171","author":"Waldman","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.tcb.2003.10.009","article-title":"Receptors and immune sensors: The complex entry path of human cytomegalovirus","volume":"14","author":"Compton","year":"2004","journal-title":"Trends Cell Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00018-008-7570-z","article-title":"Entry of herpesviruses into mammalian cells","volume":"65","author":"Heldwein","year":"2008","journal-title":"Cell Mol. Life Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nm1236","article-title":"Integrin alphavbeta3 is a coreceptor for human cytomegalovirus","volume":"11","author":"Wang","year":"2005","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1128\/JVI.01422-06","article-title":"Human cytomegalovirus tropism for endothelial cells: Not all endothelial cells are created equal","volume":"81","author":"Jarvis","year":"2007","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1099\/jgv.0.000882","article-title":"The pentameric complex of human Cytomegalovirus: Cell tropism, virus dissemination, immune response and vaccine development","volume":"98","author":"Gerna","year":"2017","journal-title":"J. Gen. Virol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gH\/gL\/UL128\/UL130\/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Wang, H.Y., Valencia, S.M., Pfeifer, S.P., Jensen, J.D., Kowalik, T.F., and Permar, S.R. (2021). Common Polymorphisms in the Glycoproteins of Human Cytomegalovirus and Associated Strain-Specific Immunity. Viruses, 13.","DOI":"10.3390\/v13061106"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Burwitz, B.J., Malouli, D., Bimber, B.N., Reed, J.S., Ventura, A.B., Hancock, M.H., Uebelhoer, L.S., Bhusari, A., Hammond, K.B., and Espinosa Trethewy, R.G. (2016). Cross-Species Rhesus Cytomegalovirus Infection of Cynomolgus Macaques. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1006014"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0065-3527(08)00405-3","article-title":"Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus","volume":"72","author":"Yue","year":"2008","journal-title":"Adv. Virus Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1093\/infdis\/jiz484","article-title":"Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development","volume":"221","author":"Roark","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.coviro.2017.08.005","article-title":"Rhesus monkeys for a nonhuman primate model of cytomegalovirus infections","volume":"25","author":"Itell","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00430-008-0074-5","article-title":"Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques","volume":"197","author":"Yue","year":"2008","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1128\/JVI.01669-12","article-title":"A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques","volume":"87","author":"Wussow","year":"2013","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1172\/jci.insight.94002","article-title":"Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys","volume":"2","author":"Nelson","year":"2017","journal-title":"JCI Insight"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00023-08","article-title":"Neuropathogenesis of congenital cytomegalovirus infection: Disease mechanisms and prospects for intervention","volume":"22","author":"Cheeran","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/fvl.10.8","article-title":"Guinea Pig Cytomegalovirus (GPCMV): A Model for the Study of the Prevention and Treatment of Maternal-Fetal Transmission","volume":"5","author":"Schleiss","year":"2010","journal-title":"Future Virol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Fisher, M.A., and Lloyd, M.L. (2020). A Review of Murine Cytomegalovirus as a Model for Human Cytomegalovirus Disease\u2014Do Mice Lie?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010214"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Koenig, J., Theobald, S.J., and Stripecke, R. (2020). Modeling Human Cytomegalovirus in Humanized Mice for Vaccine Testing. Vaccines, 8.","DOI":"10.3390\/vaccines8010089"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"636775","DOI":"10.3389\/fimmu.2021.636775","article-title":"Humanized Mice for the Evaluation of Novel HIV-1 Therapies","volume":"12","author":"Abeynaike","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2011.01.001","article-title":"A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease","volume":"140","author":"Washburn","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-1-0716-1111-1_17","article-title":"Development of a huBLT Mouse Model to Study HCMV Latency, Reactivation, and Immune Response","volume":"2244","author":"Crawford","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.3389\/fimmu.2018.02734","article-title":"Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34(+) Cells","volume":"9","author":"Theobald","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"619236","DOI":"10.3389\/fimmu.2020.619236","article-title":"Advances in Human Immune System Mouse Models for Studying Human Hematopoiesis and Cancer Immunotherapy","volume":"11","author":"Mian","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"567531","DOI":"10.3389\/fimmu.2020.567531","article-title":"Harnessing T Cells to Control Infections After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"11","author":"Basso","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1002\/cti2.1249","article-title":"Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant","volume":"10","author":"Gottlieb","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1038\/emi.2016.97","article-title":"Converting monoclonal antibody-based immunotherapies from passive to active: Bringing immune complexes into play","volume":"5","author":"Lambour","year":"2016","journal-title":"Emerg. Microbes Infect."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/978-1-4939-8648-4_24","article-title":"The Use of Somatic Hypermutation for the Affinity Maturation of Therapeutic Antibodies","volume":"1827","author":"Bowers","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cell.2019.03.016","article-title":"B Cell Responses: Cell Interaction Dynamics and Decisions","volume":"177","author":"Cyster","year":"2019","journal-title":"Cell"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fimmu.2018.00117","article-title":"Insights into the Structural Basis of Antibody Affinity Maturation from Next-Generation Sequencing","volume":"9","author":"Mishra","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Sauna, Z.E., and Kimchi-Sarfaty, C. (2017). Characterization of Therapeutic Proteins. Protein Therapeutics, Springer International Publishing.","DOI":"10.1007\/978-3-319-41818-6"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Bootz, A., Karbach, A., Spindler, J., Kropff, B., Reuter, N., Sticht, H., Winkler, T.H., Britt, W.J., and Mach, M. (2017). Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006601"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"6273","DOI":"10.1073\/pnas.1800224115","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"115","author":"Baraniak","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1073\/pnas.1800177115","article-title":"HCMV glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions","volume":"115","author":"Nelson","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"101427","DOI":"10.1016\/j.smim.2020.101427","article-title":"Quantum leap of monoclonal antibody (mAb) discovery and development in the COVID-19 era","volume":"50","author":"Pecetta","year":"2020","journal-title":"Semin. Immunol."},{"key":"ref_54","unstructured":"(2021, July 29). Cytogam Prescribing Information, Available online: https:\/\/www.fda.gov\/media\/77671\/download."},{"key":"ref_55","unstructured":"Stratton, K., Durch, J., and Lawrence, R. (2000). Vaccines for the 21st Century: A Tool for Decision Making, National Academy Press."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/infdis\/jiz428","article-title":"Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease","volume":"221","author":"Nelson","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/infdis\/134.5.470","article-title":"Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus","volume":"134","author":"Plotkin","year":"1976","journal-title":"J. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/infdis\/171.1.26","article-title":"Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age","volume":"171","author":"Adler","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/infdis\/159.5.860","article-title":"Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge","volume":"159","author":"Plotkin","year":"1989","journal-title":"J. Infect. Dis."},{"key":"ref_60","first-page":"1176","article-title":"Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients","volume":"58","author":"Plotkin","year":"1994","journal-title":"Transplantation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.vaccine.2015.11.056","article-title":"Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial","volume":"34","author":"Bernstein","year":"2016","journal-title":"Vaccine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/infdis\/jir138","article-title":"Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women","volume":"203","author":"Sabbaj","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J. Exp. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1093\/infdis\/jiz523","article-title":"Scientific and Regulatory Considerations for Efficacy Studies of Cytomegalovirus Vaccines","volume":"221","author":"Krause","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"362ra145","DOI":"10.1126\/scitranslmed.aaf9387","article-title":"A replication-defective human cytomegalovirus vaccine for prevention of congenital infection","volume":"8","author":"Wang","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ourahmane, A., Cui, X., He, L., Catron, M., Dittmer, D.P., Al Qaffasaa, A., Schleiss, M.R., Hertel, L., and McVoy, M.A. (2019). Inclusion of Antibodies to Cell Culture Media Preserves the Integrity of Genes Encoding RL13 and the Pentameric Complex Components During Fibroblast Passage of Human Cytomegalovirus. Viruses, 11.","DOI":"10.3390\/v11030221"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1128\/JVI.02033-16","article-title":"Neutralization of Diverse Human Cytomegalovirus Strains Conferred by Antibodies Targeting Viral gH\/gL\/pUL128-131 Pentameric Complex","volume":"91","author":"Ha","year":"2017","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/infdis\/jiz141","article-title":"Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects","volume":"220","author":"Adler","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1128\/JVI.00747-19","article-title":"A Replication-Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection","volume":"93","author":"Liu","year":"2019","journal-title":"J. Virol."},{"key":"ref_72","first-page":"631","article-title":"Functional Evaluation and Genetic Evolution of Human T-cell Responses after Vaccination with a Conditionally Replication-Defective Cytomegalovirus Vaccine","volume":"7","author":"Cox","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_73","unstructured":"(2021, July 29). GSK, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01357915?cond=cytomegalovirus+gsk&draw=2&rank=1."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1093\/infdis\/jiz447","article-title":"The Status of Vaccine Development Against the Human Cytomegalovirus","volume":"221","author":"Plotkin","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1128\/CVI.00662-13","article-title":"Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity","volume":"21","author":"Kirchmeier","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_76","unstructured":"(2021, July 29). VBI, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02826798?cond=cytomegalovirus+vbi&draw=2&rank=1."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/infdis\/jit105","article-title":"Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: A randomized, controlled trial","volume":"207","author":"Walsh","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/blood-2016-07-729756","article-title":"MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults","volume":"129","author":"Longmate","year":"2017","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"306","DOI":"10.7326\/M19-2511","article-title":"Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial","volume":"172","author":"Aldoss","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nm.2104","article-title":"Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity","volume":"16","author":"Flatz","year":"2010","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Schleiss, M.R., Berka, U., Watson, E., Aistleithner, M., Kiefmann, B., Mangeat, B., Swanson, E.C., Gillis, P.A., Hernandez-Alvarado, N., and Fernandez-Alarcon, C. (2017). Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B\/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector. Clin. Vaccine Immunol., 24.","DOI":"10.1128\/CVI.00300-16"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Schwendinger, M., Thiry, G., De Vos, B., Leroux-Roels, G., Bruhwyler, J., Huygens, A., Ganeff, C., Buchinger, H., Orlinger, K.K., and Pinschewer, D.D. (2020). A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus. J. Infect. Dis.","DOI":"10.1093\/infdis\/jiaa121"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Blakney, A.K., Ip, S., and Geall, A.J. (2021). An Update on Self-Amplifying mRNA Vaccine Development. Vaccines, 9.","DOI":"10.3390\/vaccines9020097"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.vaccine.2014.05.004","article-title":"Human cytomegalovirus gH\/gL\/UL128\/UL130\/UL131A complex elicits potently neutralizing antibodies in mice","volume":"32","author":"Wen","year":"2014","journal-title":"Vaccine"},{"key":"ref_89","unstructured":"(2021, July 29). Cytotect Prescribing Information. Available online: https:\/\/www.sps.nhs.uk\/medicines\/cytomegalovirus-immunoglobulin\/."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"558","DOI":"10.12659\/AOT.898050","article-title":"Functional Properties of Human Cytomegalovirus Hyperimmunoglobulin and Standard Immunoglobulin Preparations","volume":"21","author":"Germer","year":"2016","journal-title":"Ann. Transplant."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/508173","article-title":"Seroprevalence of cytomegalovirus infection in the United States, 1988\u20131994","volume":"43","author":"Staras","year":"2006","journal-title":"Clin. Infect. Dis"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00007890-197901000-00017","article-title":"Cytomegalovirus immune globulin: Production from selected normal donor blood","volume":"27","author":"Zaia","year":"1979","journal-title":"Transplantation"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J. Am. Chem. Soc."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1021\/ja01170a048","article-title":"The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma","volume":"71","author":"Oncley","year":"1949","journal-title":"J. Am. Chem Soc."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/TP.0b013e318224115e","article-title":"Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations","volume":"92","author":"Planitzer","year":"2011","journal-title":"Transplantation"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e26420","DOI":"10.1002\/pbc.26420","article-title":"The role of immunoglobulin prophylaxis for prevention of cytomegalovirus infection in pediatric hematopoietic stem cell transplantation recipients","volume":"64","author":"Goldstein","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0041-1345(01)02920-7","article-title":"Prevention of cytomegalovirus infection and disease in high-risk renal transplant recipients with polyvalent intravenous immunoglobulins","volume":"34","author":"Sechet","year":"2002","journal-title":"Transplant. Proc."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biologicals.2017.09.004","article-title":"Binding and neutralizing anti-cytomegalovirus activities in immune globulin products","volume":"50","author":"Wang","year":"2017","journal-title":"Biologicals"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/vox.12246","article-title":"In vitro evaluation of cytomegalovirus-specific hyperimmune globulins vs. standard intravenous immunoglobulins","volume":"109","author":"Miescher","year":"2015","journal-title":"Vox Sang."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1034\/j.1399-3062.2001.00006.x","article-title":"Antibody inhibition of cytomegalovirus: The role of natural killer and macrophage effector cells","volume":"3","author":"Forthal","year":"2001","journal-title":"Transpl. Infect. Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41541-017-0038-0","article-title":"Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB\/MF59 vaccination","volume":"2","author":"Li","year":"2017","journal-title":"NPJ Vaccines"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.micinf.2009.07.010","article-title":"Recombinant human monoclonal antibodies to human cytomegalovirus glycoprotein B neutralize virus in a complement-dependent manner","volume":"11","author":"Ohta","year":"2009","journal-title":"Microbes Infect."},{"key":"ref_103","first-page":"31","article-title":"Cytomegalovirus prophylaxis with ganciclovir, acyclovir, and CMV hyperimmune globulin in liver transplant patients receiving OKT3 induction","volume":"27","author":"Ham","year":"1995","journal-title":"Transplant. Proc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Coppola, T., Mangold, J.F., Cantrell, S., and Permar, S.R. (2019). Impact of Maternal Immunity on Congenital Cytomegalovirus Birth Prevalence and Infant Outcomes: A Systematic Review. Vaccines, 7.","DOI":"10.3390\/vaccines7040129"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","article-title":"A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus","volume":"370","author":"Revello","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/uog.19164","article-title":"Prevention of maternal-fetal transmission of cytomegalovirus after primary maternal infection in the first trimester by biweekly hyperimmunoglobulin administration","volume":"53","author":"Kagan","year":"2019","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1056\/NEJMc1405377","article-title":"Hyperimmune globulin to prevent congenital CMV infection","volume":"370","author":"Hamprecht","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ajog.2020.02.018","article-title":"Cytomegalovirus infection during pregnancy: State of the science","volume":"223","author":"Foulon","year":"2020","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13052-017-0358-8","article-title":"Congenital Cytomegalovirus infection: Advances and challenges in diagnosis, prevention and treatment","volume":"43","author":"Marsico","year":"2017","journal-title":"Ital. J. Pediatr."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0166-3542(94)90048-5","article-title":"Human monoclonal anti-cytomegalovirus (CMV) antibody (MSL 109): Enhancement of in vitro foscarnet- and ganciclovir-induced inhibition of CMV replication","volume":"24","author":"Nokta","year":"1994","journal-title":"Antivir. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/00002030-200204120-00007","article-title":"HIV and cytomegalovirus viral load and clinical outcomes in AIDS and cytomegalovirus retinitis patients: Monoclonal Antibody Cytomegalovirus Retinitis Trial","volume":"16","author":"Jabs","year":"2002","journal-title":"AIDS"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1128\/AAC.00523-15","article-title":"Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of RG7667, an Anticytomegalovirus Combination Monoclonal Antibody Therapy, in Healthy Adults","volume":"59","author":"Ishida","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Ishida, J.H., Patel, A., Mehta, A.K., Gatault, P., McBride, J.M., Burgess, T., Derby, M.A., Snydman, D.R., Emu, B., and Feierbach, B. (2017). Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01794-16"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00382-16","article-title":"In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539","volume":"60","author":"Patel","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Maertens, J., Logan, A.C., Jang, J., Long, G., Tang, J.L., Hwang, W.Y.K., Koh, L.P., Chemaly, R., Gerbitz, A., and Winkler, J. (2020). Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.02467-19"},{"key":"ref_117","unstructured":"(2021, July 29). FDA Approves First Treatment for Ebola Virus, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-ebola-virus."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/8728\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:45:52Z","timestamp":1760165152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/8728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,13]]},"references-count":117,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijms22168728"],"URL":"https:\/\/doi.org\/10.3390\/ijms22168728","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,13]]}}}